At the end of the 28 days of subcutaneous injection of testosterone propionate, there was a significant increase (p < 0.05) in PSA level (initial PSA) in groups that received the hormone compared to the normal control, indicating successful induction of BPH. The gene discussed is KLK3; the disease is benign prostatic hyperplasia.